Piotr Smolewski Selected Research

IRS 954

6/2013

Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Piotr Smolewski Research Topics

Disease

34	Neoplasms (Cancer) 10/2020 - 05/2004
20	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2022 - 05/2003
9	Lymphoma (Lymphomas) 06/2021 - 05/2004
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 12/2004
8	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 07/2003
7	Multiple Myeloma 02/2021 - 08/2008
6	Leukemia 09/2009 - 01/2002
5	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 01/2015
5	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 05/2019 - 05/2004
5	Breast Neoplasms (Breast Cancer) 12/2018 - 10/2011
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 10/2017 - 07/2004
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2016 - 12/2009
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2015 - 12/2013
3	Essential Thrombocythemia 12/2012 - 12/2009
2	Febrile Neutropenia 01/2022 - 01/2018
2	T-Cell Lymphoma (Lymphoma, T Cell) 06/2021 - 01/2017
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2015
2	Disease Progression 05/2018 - 07/2006
2	Necrosis 06/2013 - 11/2002
2	Thrombosis (Thrombus) 06/2010 - 12/2009
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2008 - 11/2005
2	Acute Promyelocytic Leukemia 05/2002 - 01/2002
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2020
1	Anemia 01/2020
1	Hypercalcemia (Milk Alkali Syndrome) 01/2020
1	Renal Insufficiency (Renal Failure) 01/2020
1	Amyloidosis 05/2019
1	Immunoglobulin Light-chain Amyloidosis 05/2019
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 05/2019
1	Hairy Cell Leukemia 01/2019

Drug/Important Bio-Agent (IBA)

14	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2002
12	Pharmaceutical PreparationsIBA 01/2017 - 12/2004
11	Monoclonal AntibodiesIBA 01/2021 - 05/2004
8	Cladribine FDA LinkGeneric 01/2019 - 05/2003
8	Rituximab (Mabthera)FDA Link 05/2018 - 05/2004
5	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 09/2006
4	Phosphotransferases (Kinase)IBA 02/2022 - 06/2006
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2018
4	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022 - 01/2018
4	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 01/2018
4	Brentuximab VedotinIBA 01/2022 - 01/2018
4	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 01/2018
4	Bortezomib (Velcade)FDA Link 02/2021 - 12/2006
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2021 - 06/2006
4	CaspasesIBA 01/2021 - 11/2002
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2018 - 05/2003
3	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2017
3	Proteasome InhibitorsIBA 02/2021 - 05/2019
3	Inhibitor of Apoptosis ProteinsIBA 01/2021 - 02/2008
3	Clofarabine (Clolar)FDA Link 12/2018 - 01/2014
3	ranpirnase (Pannon)IBA 07/2014 - 02/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2013 - 06/2010
2	Agammaglobulinaemia Tyrosine KinaseIBA 02/2022 - 01/2021
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 01/2018
2	idelalisibIBA 01/2021 - 10/2020
2	Protein Isoforms (Isoforms)IBA 10/2020 - 12/2006
2	CytokinesIBA 01/2020 - 07/2004
2	retinoic acid receptor betaIBA 12/2018 - 01/2014
2	PhytochemicalsIBA 12/2018 - 01/2015
2	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2017 - 01/2014
2	Cytotoxins (Cytolysins)IBA 01/2017 - 03/2012
2	Cytostatic AgentsIBA 01/2016 - 02/2010
2	CD20 AntigensIBA 01/2016 - 05/2004
2	Immunomodulating AgentsIBA 09/2015 - 01/2015
2	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2015 - 09/2014
2	SurvivinIBA 01/2015 - 02/2008
2	SMIP-016IBA 10/2014 - 12/2009
2	fludarabineIBA 01/2014 - 12/2004
2	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 11/2002
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2009 - 08/2008
2	Etodolac (Lodine)FDA LinkGeneric 08/2008 - 12/2006
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 09/2006 - 11/2005
2	Purine NucleosidesIBA 01/2005 - 12/2004
2	Retinoic Acid Receptor alphaIBA 05/2002 - 01/2002
2	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 05/2002 - 01/2002
1	Messenger RNA (mRNA)IBA 02/2021
1	duvelisibIBA 01/2021
1	venetoclaxIBA 01/2021
1	ibrutinibIBA 01/2021
1	acalabrutinibIBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 09/2020
1	Interleukin-8 (Interleukin 8)IBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2020
1	ChemokinesIBA 01/2020
1	CalciumIBA 01/2020
1	ixazomibIBA 05/2019
1	Lenalidomide (CC 5013)FDA Link 05/2019
1	Dexamethasone (Maxidex)FDA LinkGeneric 05/2019
1	Investigational DrugsIBA 05/2019

Therapy/Procedure

16	Therapeutics 01/2022 - 05/2004
10	Drug Therapy (Chemotherapy) 06/2021 - 09/2006
3	Immunotherapy 01/2018 - 01/2015
2	Hematopoietic Stem Cell Transplantation 08/2014 - 09/2013
1	Transplantation 01/2022
1	Oral Administration 05/2019
1	Stem Cell Transplantation 05/2019